# Sutro Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/STRO/sutro-biopharma-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-70f1b4d0
Ticker: STRO
Company: Sutro Biopharma
Source: Sutro Biopharma
Published: 2026-01-07 21:05 EST
## Summary

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology...

## Article Body
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Jane Chung, Chief Executive Officer, will present at the 44 th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 11:15 AM PT / 2:15 PM ET in San Francisco, CA.

A live webcast of the presentation will be accessible through the Events & Presentations page of the Investor Relations section of the Company’s website at www.sutrobio.com . An archived replay will be available for at least 30 days after the event.

About Sutro Biopharma Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies. For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com .
## Recent Company News
- 2026-05-14 20:05 EST — [Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights](https://biopharmsignal.com/news/STRO/sutro-biopharma-reports-first-quarter-2026-financial-results-and-business-highli-43d18eb3) — Source: Sutro Biopharma
- 2026-04-19 23:45 EST — [Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026](https://biopharmsignal.com/news/STRO/sutro-biopharma-presents-promising-preclinical-data-across-its-pipeline-of-next--bdf8f4ce) — Source: Sutro Biopharma
- 2026-03-23 20:05 EST — [Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights](https://biopharmsignal.com/news/STRO/sutro-biopharma-reports-full-year-2025-financial-results-and-business-highlights-c81ab4c5) — Source: Sutro Biopharma
- 2026-02-25 13:30 EST — [Sutro Biopharma to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/STRO/sutro-biopharma-to-participate-in-upcoming-investor-conferences-5470cd63) — Source: Sutro Biopharma
- 2026-02-23 13:30 EST — [Sutro Biopharma Announces Participation at the 16th World ADC London Summit](https://biopharmsignal.com/news/STRO/sutro-biopharma-announces-participation-at-the-16th-world-adc-london-summit-c229d910) — Source: Sutro Biopharma
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)